This grant is intended to support research investigators who have bladder cancer research projects in the United States that 1) previously have been scientifically reviewed, approved, and funded, but which have been interrupted by terminations in federal funding; or 2) previously have been scientifically reviewed by the National Institutes of Health (NIH) within the past 18 months and are imminently fundable but failed to receive federal funding due to funding constraints or changes in the corresponding funding mechanism.
Specifically, the 2026 BCAN Continuity Grant is soliciting research projects that have direct applicability and relevance to bladder cancer and/or upper tract urothelial carcinoma. These projects may be basic, translational, clinical, or epidemiological in nature, or for patient-oriented clinical bladder cancer research projects (e.g. studies of shared decision making, access to care, quality of care, quality of life, health disparities, comparative effectiveness research, patient-centered outcomes research, and survivorship). BCAN will not re-scrutinize the scientific merit of projects that have lost federal funding.